Corona Remedies IPO Details
Corona Remedies IPO Summary
Corona Remedies IPO opens for subscription on 08 Dec 2025 and closes on 10 Dec 2025.The IPO will be listed on NSE, BSE with the tentative listing date set for 15 Dec 2025.
Corona Remedies IPO price band has been fixed at ₹1008 – ₹1062 per share. The face value is ₹10 per share with a lot size of 14.
Corona Remedies IPO total issue size comprises 61,71,102 shares (aggregating up to ₹655.37 Cr.). Offer for Sale consists of 61,71,102 shares (aggregating up to ₹655.37 Cr.). Pre-issue shareholding stands at 6,11,60,088, which will increase to 6,11,60,088 post-issue.
Corona Remedies IPO carries a ₹342 (32.2%) GMP, reflecting investor sentiment.
Corona Remedies IPO Lot Size :Retail Minimum is 1 lot (14 shares) amounting to ₹14,868. Retail Maximum is 13 lots (182 shares) amounting to ₹193,284. SHNI Minimum is 14 lots (196 shares) amounting to ₹208,152. SHNI Maximum is 67 lots (938 shares) amounting to ₹996,156. BHNI Minimum is 68 lots (952 shares) amounting to ₹1,011,024.
The Lead Managers for Corona Remedies IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Kotak Mahindra Capital Company Ltd, Jm Financial Ltd, IIFL Capital Services Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Corona Remedies Limited RHP.
Corona Remedies IPO Details
Corona Remedies IPO Subscription
Corona Remedies IPO Application Wise Breakup (Approx)
Corona Remedies IPO Dates
- 08 Dec 2025Opening dateOpen
- 10 Dec 2025Closing dateClose
- 11 Dec 2025Allotment Date Allotment
- 12 Dec 2025Initiation of RefundsRefund
- 12 Dec 2025Credit of SharesCredit
- 15 Dec 2025Listing dateListing
Corona Remedies IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 14 | ₹14,868 |
| Retail Maximum | 13 | 182 | ₹193,284 |
| SHNI Minimum | 14 | 196 | ₹208,152 |
| SHNI Maximum | 67 | 938 | ₹996,156 |
| BHNI Minimum | 68 | 952 | ₹1,011,024 |
Corona Remedies IPO Reservation
Promoter Holding
Documents
Corona Remedies IPO Valuations
Corona Remedies Financial Information
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| NET Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
| Amount in ₹ Crore | ||||
About Corona Remedies IPO
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company focused on the development, manufacturing, and marketing of a diversified range of products across key therapeutic segments, including women’s health, cardiology, pain management, urology, and multiple specialty areas.
Product Portfolio
As of June 30, 2025, the company’s portfolio included 71 brands across:
Women’s healthcare
Cardio-diabeto therapies
Pain management and urology
Multispecialty segments, such as vitamins and minerals, gastrointestinal care, nutrition, and respiratory therapies
This broad product mix positions Corona Remedies as a multi-category player within the Indian Pharmaceutical Market (IPM).
Pan-India Presence
Corona Remedies has a robust nationwide marketing and distribution network, supported by 2,671 medical representatives operating across 22 states. This extensive field force enables strong engagement with healthcare professionals, hospitals, and clinics, driving deep market penetration in its focus therapeutic areas.
Manufacturing Capabilities
The company operates two manufacturing facilities in Gujarat, with a combined installed capacity of 1,285.44 million formulation units per year. These facilities support scalable production, quality assurance, and the company’s expanding product demand across India.
Strength Of Corona Remedies IPO
- Second fastest growing company within the top 30 pharmaceutical companies in the Indian pharmaceutical market by domestic sales between MAT June 2022 and MAT June 2025.
- Demonstrated capabilities of building a diversified portfolio, including "engine" brands, in our targeted therapy areas.
- Pan-India sales network and marketing strategy focused on the "middle of the pyramid" target market.
- Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
- Qualified, experienced and entrepreneurial management team supported by marquee investors.
Risk Of Corona Remedies IPO
- The therapeutic areas of women's healthcare, cardio-diabeto and pain management contributed to an aggregate of Rs.2,257.26 million (or 65.14%) and Rs.7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.
- Our 27 "engine" brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our "engine" brands could have an adverse effect on our business, results of operations, financial condition and cash flows.
- We derive a significant majority of our revenue from our operations within India (constituting 96.34% and 96.33% of our revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for our products in India, or if we fail to successfully expand into international markets, our business, results of operations, financial conditions and cash flows may be adversely affected.
- A significant portion of our domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh (accounting for 47.30% of our domestic sales for MAT June 2025). Any adverse developments affecting our sales in these regions could have an adverse effect on our business, results of operations, financial condition and cash flows.
- 70.10% of our domestic sales for MAT June 2025 were derived from chronic and sub-chronic therapeutic segments, which are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and cash flows.
- We depend on third-party suppliers to procure our raw materials and finished goods, with whom we do not have long term contracts, with our total purchases aggregating to 19.87% and 27.96% of our total expenses for the three months ended June 30, 2025 and the Financial Year 2025, respectively. Further, we rely on La Chandra Pharmalab Private Limited, our Associate and Group Company, for the supply of certain active pharmaceutical ingredients in our women's healthcare therapeutic area. We cannot assure you that we will be in a position to fully control or direct the operations of such suppliers to ensure an uninterrupted supply of raw materials and APIs.
- As of June 30, 2025, with a portfolio of 71 brands, we held 194 registered trademarks, with 29 pending trademark applications and 67 opposed/ objected/ refused / abandoned trademarks under certain classes of trademarks. If we are unable to obtain trademarks for our products and brands or protect other proprietary information, our business, results of operations, financial condition and cash flows may be adversely affected.
- We are required to obtain, maintain or renew our statutory and regulatory licenses, permits and approvals required to operate our operations. If we fail to obtain, maintain or renew the required licenses, permits and approvals, it may adversely affect our business, results of operations, financial condition and cash flows.
- Proceeds from the Offer will not be available to us.
- As of June 30, 2025, we engaged 22 carrying and forwarding agents for the sale of our products across the regions in which we market our products, with our five largest C&F agents contributing to 43.30% and 44.35% of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025. The loss of our C&F agents, the deterioration of their financial condition or prospects, a reduction in their demand for our products or our inability to maintain and increase the number of our arrangements for the distribution of our products could adversely affect our business, results of operations, financial conditions and cash flows.
Objectives Corona Remedies IPO
To be announced
Company Contact Details
Corona Remedies Ltd.
CORONA House, C – Mondeal Business Park
Near Gurudwara S. G. Highway
Thaltej Ahmedabad, Gujarat, 380059
Phone: +91 79 4023 3000
Email: complianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/
Registrar Contact Details
Corona Remedies FAQs
The Corona Remedies IPO is a MAINBOARD public issue comprising 6171102 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹655.37 Cr.. The issue price has been fixed at ₹1062 per equity share, and the minimum application size is 14 shares.
The IPO opens for subscription on 08 Dec 2025, and closes on 10 Dec 2025.
Bigshare Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at ₹342 (32.2%).
Quick Links
Comments
